Clinical trials: Non-small Cell Carcinoma
Non-Small Cell Lung Cancer
A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer
The primary objective of the study is to compare overall survival of participants randomized to receiving custirsen in combination with docetaxel with participants randomized to receive docetaxel alone.
- Trial name
- ENSPIRIT (NCT01630733)
- Testing
- Custirsen, Docetaxel
- Where
- 78 sites in United States, Australia and 12 more
- Volunteers
- 664 people
- Sponsor
- Achieve Life Sciences
Advanced Non-small Cell Lung Cancer
Immunotherapy With Racotumomab Versus Support Treatment in Advanced Non-small Cell Lung Cancer Patients
This study is designed to evaluate safety and immunogenicity of racotumomab in patients with advanced Non-small Cell Lung Cancer (NSCLC), in concomitance with chemotherapy (docetaxel) when a second-line therapy is indicated.
- Trial name
- NCT01240447
- Testing
- racotumomab, Best support treatment
- Where
- Argentina
- Volunteers
- 7 people
- Sponsor
- Laboratorio Elea Phoenix S.A.
Advanced Malignant Solid Tumor, Advanced Lung Cancer
A Clinical Study of BT02 in Treating Patients With Advanced Lung Cancer
The goal of this clinical trial is to assess whether an investigational treatment is safe and tolerable for patients with advanced lung cancer, and to get a preliminary idea of its effectiveness.
- Conditions
- Advanced Malignant Solid Tumor, Advanced Lung Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT07110363
- Testing
- BT02
- Volunteers
- 58 people
- Sponsor
- Biotroy Therapeutics
Non-Squamous Non-Small Cell Lung Cancer
AVAdeno Study: An Observational Study of First-Line Avastin (Bevacizumab) in Patients With Adenocarcinoma of the Lung
This prospective observational study will evaluate the efficacy and safety of first-line Avastin (bevacizumab) in combination with platinum-based chemotherapy in different age groups (<60, 60-69, 70-79, >80 years) in patients…
- Trial name
- NCT01827852
- Where
- Germany
- Volunteers
- 1,107 people
- Sponsor
- Hoffmann-La Roche
Ovarian Cancer, Renal Cancer
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
The primary objectives of this Phase 1b/2 study were as follows: Phase 1b (Bolus and Infusion): To evaluate the safety and tolerability of carfilzomib in patients with relapsed solid tumors and in patients with relapsed and/or…
- Conditions
- Ovarian Cancer, Renal Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT00531284
- Testing
- Carfilzomib, Dexamethasone
- Where
- 7 sites in United States
- Volunteers
- 184 people
- Sponsor
- Amgen
Small Cell Lung Cancer, Non-small Cell Lung Cancer
A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
This amended expansion phase of the protocol is to further the experience at a dose level of 150 mg CPT eq/m2 in patients with Stage IV non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) and to test for…
- Trial name
- NCT00455052
- Testing
- XMT-1001
- Where
- 12 sites in United States
- Volunteers
- 30 people
- Sponsor
- Mersana Therapeutics
Non-small Cell Lung Cancer
Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer
Lung cancer remains the most frequent cause of cancer death in both men and women in the world. Surgical resection using lobectomy with mediastinal lymph node dissection or sampling has been a standard of care for operable early…
- Trial name
- STARS (NCT00840749)
- Testing
- CyberKnife Stereotactic Radiotherapy, Surgery
- Where
- 19 sites in United States, China and 2 more
- Volunteers
- 36 people
- Sponsor
- Accuray Incorporated
Non-Small Cell Lung Cancer
A Study of Thymidylate Synthase Expression in Patients With Non-Small Cell Lung Cancer
Thymidylate synthase (TS) is a substance the body produces naturally. The purpose of this research is to determine if there is a link between TS production and how well patients respond to treatment of non-squamous non-small cell…
- Trial name
- NCT00887549
- Testing
- pemetrexed, cisplatin
- Where
- 14 sites in Ireland, United Kingdom
- Volunteers
- 70 people
- Sponsor
- Eli Lilly and Company
Immunotherapy, Cancer
Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02)
The primary objective of this study is to develop and train the Elephas live tumor diagnostic platform and determine the ex-vivo accuracy of the Elephas Score using in-vivo RECIST 1.1 as the reference method
- Conditions
- Immunotherapy, Cancer, Bladder Cancer, Urothelial Carcinoma Bladder
- Trial name
- ELEPHAS-02 (NCT05520099)
- Testing
- Core Needle Biopsy, Forceps Biopsy, Punch Biopsy
- Where
- 12 sites in United States
- Volunteers
- 416 people
- Sponsor
- Elephas
Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
A first-in-human study using BDC-3042 as a single agent and in combination with cemiplimab in patients with advanced malignancies
- Conditions
- Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma, Ovarian Cancer, Head and Neck Cancer
- Trial name
- NCT06052852
- Testing
- BDC-3042, Cemiplimab
- Where
- 6 sites in United States
- Volunteers
- 17 people
- Sponsor
- Bolt Biotherapeutics, Inc.
Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal
A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies
The purpose of this study is to learn about the safety and the effects of PF-08046037 alone or with sasanlimab for the treatment of certain advanced or metastatic malignancies.
- Conditions
- Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal, Malignant Melanoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Trial name
- NCT06974734
- Testing
- PF-08046037, sasanlimab
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 8 people
- Sponsor
- Pfizer
Non-small Cell Lung Cancer
Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of Simotinib Hydrochloride in Patients With Advanced NSCLC
The primary objective is to assess the safety and tolerability of multiple doses of Simotinib Hydrochloride in NSCLC patients. The secondary objective is to determine the pharmacokinetic (PK) profile and explore the preliminary…
- Trial name
- NCT01772732
- Testing
- Simotinib Hydrochloride
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Nonsquamous Non-small Cell Lung Cancer
Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)
The purpose of this study is to assess the safety and efficacy of pemetrexed + platinum chemotherapy + pembrolizumab (MK-3475) with or without lenvatinib (MK-7902/E7080) as first-line intervention in adults with metastatic…
- Trial name
- NCT03829319
- Testing
- Pembrolizumab, Carboplatin, Cisplatin
- Where
- 158 sites in United States, Argentina and 15 more
- Volunteers
- 761 people
- Sponsor
- Merck Sharp & Dohme LLC
Non Small Cell Lung Cancer, Colorectal Cancer
A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations
A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS or EGFR mutations to determine the maximum tolerated dose and recommended Phase II dose of HBI-2376 and characterize its pharmacokinetic…
- Conditions
- Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor
- Trial name
- NCT05163028
- Testing
- HBI-2376
- Where
- 12 sites in United States, Puerto Rico
- Volunteers
- 42 people
- Sponsor
- HUYABIO International, LLC.
Non-Small-Cell Lung Carcinoma
Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.
Enzastaurin given daily to patients with non-small cell lung cancer who have failed at least one prior therapy.
- Trial name
- NCT00105092
- Testing
- Enzastaurin HCL
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Eli Lilly and Company
Non-Small Cell Lung Cancer
A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC
The primary purpose of this research study is to evaluate how safe, how well tolerated and how effective a range of doses of L-DOS47 in combination with standard doublet therapy of pemetrexed/carboplatin in patients with Stage IV…
- Trial name
- NCT02309892
- Testing
- L-DOS47
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Helix BioPharma Corporation
Bladder Carcinoma, Ureter Carcinoma
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors.
- Conditions
- Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer
- Trial name
- ORACLE (NCT05059444)
- Testing
- Guardant Reveal
- Where
- 57 sites in United States, France and 3 more
- Volunteers
- 2,285 people
- Sponsor
- Guardant Health, Inc.
Non-small Cell Lung Cancer, Solid Tumors
Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)
This is a phase 1 trial of the safety, tolerability, and pharmacokinetics (PK) of sacituzumab tirumotecan monotherapy, and of sacituzumab tirumotecan in combination with pembrolizumab (MK-3475) or pembrolizumab + carboplatin, in…
- Conditions
- Non-small Cell Lung Cancer, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1), Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)
- Trial name
- TroFuse-008 (NCT06049212)
- Testing
- Sacituzumab tirumotecan, Pembrolizumab, Supportive care measures
- Where
- 7 sites in Japan
- Volunteers
- 30 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-squamous Non-small Cell Lung Cancer
A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung Cancer
This is a Phase III, randomized, double blind, multicenter, active comparator, parallel two arm study to compare the efficacy, and to evaluate the safety, and immunogenicity of BAT1706 to EU Avastin® in patients with previously…
- Trial name
- NCT03329911
- Testing
- EU Avastin®, BAT1706, Paclitaxel
- Where
- 5 sites in China, Mexico and 3 more
- Volunteers
- 651 people
- Sponsor
- Bio-Thera Solutions
Cervical Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P03 monotherapy in adult…
- Conditions
- Cervical Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer, Colorectal Cancer, Intrahepatic Cholangiocarcinoma
- Trial name
- NCT07169734
- Testing
- ALE.P03
- Where
- 41 sites in United States, France and 6 more
- Volunteers
- 180 people
- Sponsor
- Alentis Therapeutics AG
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.